Document:

Exhibit 10.1

    

    
       

      

      TECHNOLOGY AND SERVICES EXCHANGE AGREEMENT

       

      THIS TECHNOLOGY AND SERVICES EXCHANGE AGREEMENT (this “Agreement”) is dated February 17, 2021, is effective as of the Effective Time
        (defined below) and is entered into by and among Quantum-Si Incorporated (“Quantum-Si”) and each entity set forth on the signature pages hereto (each such entity is a “Participant”),

        and any additional entities that become Participants in accordance with Section 5.

       

      	1.	
              DEFINITIONS

            

       

      “Confidential Information” means information, ideas, data or know-how, whether provided in written, oral, visual or other form, and whether provided
        affirmatively by one party to another pursuant to this Agreement, or indirectly through access to facilities, equipment or materials shared by the parties.  Confidential Information shall not include any such information, idea, data or know-how
        that (i) is already known to the receiving party (other than under an obligation of confidentiality) at the time of disclosure, (ii) is or becomes generally available to the public other than through any
        act or omission of the receiving party, (iii) is disclosed to the receiving party by a third party who had no separate nondisclosure obligation in respect of such information, idea, data or know-how, or (iv) is independently discovered or developed
        by or on behalf of the receiving party without use of the Confidential Information of the disclosing party.

       

      “Effective Time” means the effective time of any merger in which Quantum-Si is a constituent party, and the other party to such merger is either (i) a
        corporate entity, the securities of which are listed on a public exchange or (ii) a direct or indirect parent company or subsidiary of a corporate entity, the securities of which are listed on a public exchange.

       

      “Non-Core Technologies” means, with respect to Quantum-Si or a Participant, any technology, information or equipment owned or otherwise controlled by
        Quantum-Si or such Participant, respectively, that are not specifically related to the core business area of Quantum-Si or such Participant, respectively.  Non-Core Technologies may include, without
        limitation, software, hardware, electronics, fabrication and supplier information, vendor lists and contractor lists.

       

      	2.	
              NON-CORE TECHNOLOGY SHARE

            

       

      2.1          Any Participant may, in its sole discretion, permit Quantum-Si to use such Participant’s Non-Core
          Technologies as set forth in a written work order entered into by and between Quantum-Si and such Participant pursuant to (and subject to) this Agreement, that describes at least (i) the Non-Core Technologies permitted to be used, (ii) the terms
          of such use and restrictions with respect to such use, (iii) any fees or other compensation payable for such use, which shall be fair market value, (iv) payment terms, and (iv) such other terms as the two parties may agree (each a “Technology Work Order”).  Quantum-Si may, in its sole discretion, permit a Participant to use Quantum-Si’s Non-Core Technologies as set forth in a Technology Work Order
          entered into by and between Quantum-Si and such Participant.  Each Technology Work Order is subject to and governed by the terms of this Agreement. In the event of a conflict between the terms of a Technology Work Order and the terms of this
          Agreement, the terms of this Agreement shall take precedence.

       

      
        
          

      

      
      2.2          Each party will use no less than reasonable care in its use of the other party’s shared Non-Core
          Technologies, and, subject to the terms of the applicable Technology Work Order and this Agreement, shall not share such Non-Core Technologies with any other party or any third party (except for consultants and contractors for use on such party’s
          behalf).  In addition, each party may allow third parties to use the other party’s Non-Core Technologies subject to the terms of the applicable Technology Work Order, but in any case only in the same manner such party is allowed to use the same
          under the applicable Technology Work Order to the extent such technologies are embedded in or required for the use by such third parties of such party’s own products or services.

       

      2.3          For avoidance of doubt, as among the parties and any third party receiving the shared Non-Core Technology
          directly or indirectly from a receiving party, ownership of Non-Core Technologies (and all intellectual property rights therein) shall remain with the party that originally shared such Non-Core Technologies.

       

      	3.	
              SHARED SERVICES

            

       

      3.1          Subject to the terms of this Agreement, Quantum-Si may, in its sole discretion, permit a Participant to
          engage the personnel of Quantum-Si, and any Participant may, in its sole discretion, permit Quantum-Si to engage the personnel of such Participant, in either case to perform professional, technical or consulting services for such party as shall
          be set forth in a written work order entered into by and between Quantum-Si and such Participant pursuant to (and referring to) this Agreement that, at least, identifies and describes (i) the personnel to perform the services, (ii) the services
          to be provided, (iii) the fees or other compensation payable for such services, which shall be fair market value, (iv) payment terms, and (v) such other terms as the two parties may agree  (each a “Services Work
            Order”).  Notwithstanding anything to the contrary in this Agreement or in any Service Work Order or Technology Work Order, no personnel engaged under this Agreement may solicit, perform, or provide, or attempt to perform or provide any
          services that compete directly or indirectly with the core business area of the Originating Participant.  Each Services Work Order is subject to and governed by the terms of this Agreement. In the event of a conflict between the terms of a
          Services Work Order and the terms of this Agreement, the terms of this Agreement shall take precedence.

       

      3.2          Subject to Section 3.1, unless otherwise agreed to by Quantum-Si and the Participant in the Services Work
          Order, all rights, title and interest in and to any inventions, works-of-authorship, idea, data or know-how invented, made, created or developed by the personnel (employees, contractors or consultants) of the party in the course of conducting
          services for the other party pursuant to a Services Work Order (the “Recipient Participant”) shall be owned by the Recipient Participant (“Created IP”).  Each
          Originating Participant (defined below) hereby makes any assignments necessary to accomplish the foregoing ownership provision, and agrees to execute any documents reasonably requested by the Recipient Participant to further effect or provide
          evidence of such assignment.  Each party agrees that it has and will have appropriate agreements with all of its personnel to fully effect the provisions of this Section 3.2. Unless otherwise agreed to by Quantum-Si and the Participant in
          the Services Work Order, each Recipient Participant hereby grants to the party that had its personnel provide the services that resulted in the creation of the Created IP (the “Originating Participant”) a
          royalty-free, perpetual, limited, worldwide, non-exclusive, sublicensable (and with respect to software, sublicensable in object code only) license to utilize the Created IP only in the core business field of the Originating Participant,
          including the license to create and use derivative works based on the Created IP in the Originating Participant’s core business field, subject to any restrictions as may be set forth in this Agreement and the applicable Services Work Order.
          Notwithstanding the foregoing, Quantum-Si and each Participant agree that no Recipient Participant will use Created IP to compete directly or indirectly in the core business area of the Originating Participant.

       

      
        2

        
          

      

      3.3          Each party agrees that all of its personnel who conduct any services hereunder for a Recipient Participant may be required by the Recipient Participant to enter into a consulting
        agreement, a nondisclosure agreement, a non-solicitation agreement and/or a noncompetition agreement with the Recipient Participant with respect to the core business field of the Recipient Participant, as reasonably determined by the Recipient
        Participant.  In the event that the obligations of each such personnel under this Agreement conflict with the obligations of such personnel under such consulting agreement and/or noncompetition agreement, as the case may be, the obligations of such
        personnel under this Agreement shall take precedence.  Notwithstanding the foregoing, unless expressly permitted under this Agreement, if any obligations of such personnel under any such consulting agreement, non-disclosure agreement and/or
        noncompetition agreement conflict with the obligations of such personnel’s employment agreement, the obligations of such employment agreement shall take precedence.

       

      	4.	
              CONFIDENTIAL INFORMATION

            

       

      4.1          Each of the parties recognizes that the Confidential Information of each other party constitutes highly
          valuable and proprietary confidential information.  Each party agrees that it will keep confidential, and will cause its employees, consultants, designees and affiliates to keep confidential, all Confidential Information of the other parties
          during the term of this Agreement and for a period of ten (10) years thereafter.  Each party shall use Confidential Information of the other parties only to conduct its business.  Each party will disclose Confidential Information of another party
          only to its employees, consultants, designees and affiliates on a “need-to-know” basis.  Such disclosures shall only be made to the extent any such persons receiving the other party’s Confidential Information are bound by written confidentiality
          obligations to maintain the confidentiality thereof and not to use such Confidential Information except as permitted by this Agreement.  Without limiting the foregoing, each party may disclose information to the extent such disclosure is
          reasonably necessary to comply with applicable laws, regulations or court orders.  Each party shall take such action to preserve the confidentiality of the other parties’ Confidential Information as it would customarily take to preserve the
          confidentiality of its own Confidential Information, using, in all such circumstances, not less than reasonable care.  Each party, upon the request of the other party but subject to such requested party’s rights under Section 7.3 will
          return all the Confidential Information disclosed or transferred to it by the other party pursuant to this Agreement within sixty (60) days of such request or, if earlier, the termination or expiration of this Agreement.  Each party, as receiving
          party, will comply with any and all third party restrictions placed on the disclosing party of which it was made aware by the disclosing party with respect to the use or disclosure of Confidential Information of the disclosing party.

       

      
        3

        
          

      

      	5.	
              ADDITIONAL PARTICIPANTS.

            

       

      5.1          Additional entities may be added as Participants to this Agreement by executing and delivering additional
          joinder counterpart signature pages to this Agreement signed by such new Participant and by Quantum-Si, and such entity shall be deemed a “Participant” for all purposes hereunder.  No action or consent by the other Participants shall be required
          for such joinder to this Agreement by such additional Participant.

       

      5.2          Quantum-Si shall not permit any entity to become a Participant if any material portion of such new entity’s
          business directly overlaps with the core business field of an existing Participant, unless such existing Participant consents to such addition.

       

      	6.	
              DISCLAIMER; NON-RELIANCE.

            

       

      6.1          EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, NONE OF THE PARTIES MAKE ANY WARRANTIES TO ANY OF THE
          OTHER PARTIES WITH RESPECT TO THE SERVICES, TECHNOLOGIES OR INFORMATION PROVIDED OR SHARED UNDER THIS AGREEMENT, EITHER EXPRESS OR IMPLIED, AND THERE ARE NO EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE.
          EACH PARTY HEREBY CONFIRMS THAT IN ENTERING INTO THIS AGREEMENT OR RECEIVING ANY SERVICES OR INFORMATION HEREUNDER, IT DID NOT RELY AND DOES NOT RELY ON ANY INFORMATION, REPRESENTATION OR WARRANTY OF ANY KIND NOT SPECIFICALLY MADE IN THIS
          AGREEMENT.

       

      	7.	
              TERM AND TERMINATION

            

       

      7.1          Term; Expiration. Unless terminated earlier as permitted herein,
          the term of this Agreement commences upon the Effective Time and expires on the fifth (5th) anniversary thereof, and thereafter shall automatically be extended for up to five (5) additional and consecutive one-year renewal terms.  For
          the avoidance of doubt, this Agreement shall not be effective if the Effective Time does not occur.

       

      7.2          Termination.  Each Participant may terminate this Agreement with
          respect to its involvement as a Participant by providing written notice of such termination to Quantum-Si at least 30 days prior to the date of termination.  Quantum-Si may terminate this Agreement for any reason or no reason by providing written
          notice of such termination to the other Participants at least 30 days prior to the date of termination.

       

      7.3          Survival. Remedies for breach, rights to accrued payments and Sections 2.2,
          2.3, 3.2, 4, 6, 7.3 and 8 shall survive any termination or expiration of this Agreement.  For avoidance of doubt, upon termination or expiration of this Agreement with respect to Quantum-Si and a
          Participant, (i) unless set forth otherwise in a Technology Work Order, Quantum-Si or such Participant, as applicable, shall continue to have the right to utilize the Non-Core Technologies that were shared with it prior to such termination or
          expiration date and (ii) the license to Created IP shall survive termination.

       

      
        4

        
          

      

      	8.	
              MISCELLANEOUS

            

       

      8.1          Limitation of Liability.  In no event shall any party be liable to
          any other party for any indirect incidental, punitive, special or consequential damages arising out of or relating to this Agreement, whether in contract, tort or otherwise, even if such party has been advised of such damages.  The aggregate and
          cumulative liability of each party to each other party for all damages arising out of or relating to this Agreement shall in no event exceed the amounts paid and payable by such party to such other party under the Technology Work Order or Service
          Work Order (as applicable) under which the liability arose.  Damages caused by a party’s breach of Section 4 or its violation of applicable laws are not limited by this Section 8.1.

       

      8.2          Governing Law/Venue. The construction, validity, performance and
          effect of this Agreement will be governed by the laws of the State of Connecticut, without regard to provisions relating to conflicts of laws. Any controversy, dispute or claim arising out of, related to or in connection with this Agreement shall
          be submitted for resolution to the exclusive jurisdiction of the United States District Court for the District of Connecticut sitting in New Haven County, or if that court is unable to exercise jurisdiction for any reason, the Connecticut State
          Courts sitting in New Haven County. Each party hereby consents to the exclusive jurisdiction of the United States District Court for the District of Connecticut and the Connecticut state courts sitting in New Haven County.  Accordingly, with
          respect to any such court action, each party:  (A) submits to the personal jurisdiction of these courts; (B) waives any other requirement (whether imposed by statute, rule of court, or otherwise) with respect to personal jurisdiction or service
          of process; and (C) waives any objection to jurisdiction based on improper venue, improper jurisdiction, inconvenient forum, violation of public policy or any other basis. Each party expressly acknowledge that any breach or threatened breach of
          any of the terms and/or conditions set forth in Section 3.2 or 4 of this Agreement will result in substantial, continuing and irreparable injury to the non-breaching party.  Therefore, in addition to any other relief to which the non-breaching
          party may be entitled, each party hereby agrees that the non-breaching party shall be entitled to temporary, preliminary and permanent injunctive or other equitable relief in the event of any such breach or threatened breach, without the need to
          post any bond.

       

      8.3          Assignment. Except as specifically permitted hereunder, neither
          this Agreement nor any right or obligation hereunder may be assigned, delegated or otherwise transferred, in whole or part, by a party without the prior express written consent of the other parties.  Each party may assign this Agreement in its
          entirety in connection with the sale of all or substantially all of its assets or business to which this Agreement relates or pursuant to a similar change of control or by operation of law.  This Agreement binds the parties’ successors and
          permitted assigns.

       

      8.4          Force Majeure.  No party shall be deemed to be in breach of this
          Agreement, or otherwise be liable to any other party, by reason of any delay in performance, or non-performance, of any of its obligations pursuant to this Agreement to the extent that such delay or non-performance is due in whole or in part to
          any act, event, omission or accident beyond the reasonable control of that party, including, without limitation, any act of God or nature (including flood, earthquake, volcanic activity or other natural disaster), extreme adverse weather
          conditions, pandemic or epidemic (whether or not declared by a governmental entity), sabotage, fire, explosion, war, riot, act of terrorism and embargo.

       

      
        5

        
          

      

      8.5          Severability.  If any provision(s) of this Agreement are or become
          invalid, are ruled illegal by any court of competent jurisdiction or are deemed unenforceable under then current applicable law from time to time in effect during the term hereof, it is the intention of the parties that such provision(s) be
          deemed to be severed from this Agreement and the remainder of this Agreement shall not be affected thereby.

       

      8.6          Status.  Nothing in this Agreement is intended or shall be deemed
          to constitute a partner, agency, employer-employee, or joint venture relationship among the parties. Each party renders services under a Services Work Order as an independent contractor and not as an employee of any other party.

       

      8.7          Further Assurances.  Each party agrees to execute, acknowledge and
          deliver such further instructions, and to do all such other acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement.

       

      8.8          Counterparts.  This Agreement may be executed simultaneously in one
          or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

       

      8.9          Entire Agreement.  This Agreement and each Technology Work Order
          and Services Work Order sets forth the entire agreement between and among the parties and supersedes all prior agreements, promises, covenants, arrangements, communications, representations or warranties, whether oral or written, by any party or
          any of the parties’ agents, with respect to the subject matter hereof.  For the avoidance of doubt, the terms of that certain Amended and Restated Technology Services Agreement dated November 11, 2020, entered into by and among Quantum-Si,
          4Catalyzer Corporation and certain other Participants does not cover the subject matter of this Agreement and is not affected by this Agreement.

       

      8.10          Miscellaneous.  No provision of this Agreement may be waived,
          amended, modified or discharged unless the parties agree to the waiver, amendment, modification or discharge in writing.  No waiver by either party at any time of any breach by the other party of any condition or provision of this Agreement to be
          performed by the other party shall be deemed a waiver of similar or dissimilar provisions or conditions at the same or at any prior or subsequent time.  All descriptive headings in this Agreement are inserted for convenience only and shall be
          disregarded in construing or applying any provision of this Agreement.  All notices required hereunder shall be in writing and shall be sent by (a) U.S. mail (first class), or (b) nationally recognized courier service (e.g., DHL, Federal
          Express), with all postage or delivery charges prepaid, and shall be addressed to the parties at their principal place of business and send to the attention of “Legal Department”, or such other address and person as may be furnished by notice in
          the manner set forth herein.

       

      
        6

        
          

      

      IN WITNESS WHEREOF, the parties have executed this Agreement, effective as of the Effective Time.

       

      	 	
              QUANTUM-SI INCORPORATED

            
	 	
              PARTICIPANT

            
	 	

            
	 	
              By:

            	
              /s/ Jonathan M. Rothberg, Ph.D

            

      	 	
              Name:

            	
              Jonathan M. Rothberg, Ph.D.

            
	 	
              Title:

            	
              Executive Chairman

            

      

      

      
        
          

      

      IN WITNESS WHEREOF, the parties have executed this Agreement, effective as of the Effective Time.

       

      	 	
              AI THERAPEUTICS, INC.

            
	 	
              PARTICIPANT

            
	 	 
	 	
              By:

            	
              /s/ Alexander Magary

            

      	 	
              Name:

            	
              Alexander Magary

            
	 	
              Title:

            	
              Assistant Secretary

            

      

      

      [Signature Page to Technology and Services Exchange Agreement]

       

      

      
        
          

      

      IN WITNESS WHEREOF, the parties have executed this Agreement, effective as of the Effective Time.

       

      	 	
              HYPERFINE RESEARCH, INC.

            
	 	
              PARTICIPANT

            
	 	 
	 	
              By:

            	
              /s/ Alexander Magary

            

      	 	
              Name:

            	
              Alexander Magary

            
	 	
              Title:

            	
              Assistant Secretary

            

      

      

      [Signature Page to Technology and Services Exchange Agreement]

      

      

      
        
          

      

      IN WITNESS WHEREOF, the parties have executed this Agreement, effective as of the Effective Time.

       

      	 	
              4BIONICS LLC

            
	 	
              PARTICIPANT

            
	 	 
	 	
              By:

            	
              /s/ Alexander Magary

            

      	 	
              Name:

            	
              Alexander Magary

            
	 	
              Title:

            	
              Assistant Secretary

            

       

      [Signature Page to Technology and Services Exchange Agreement]

      

      

      
        
          

      

      IN WITNESS WHEREOF, the parties have executed this Agreement, effective as of the Effective Time.

       

      	 	
              TESSERACT HEALTH, INC.

            
	 	
              PARTICIPANT

            
	 	 
	 	
              By:

            	
              /s/ Alexander Magary

            

      	 	
              Name:

            	
              Alexander Magary

            
	 	
              Title:

            	
              Assistant Secretary

            

      

      

      [Signature Page to Technology and Services Exchange Agreement]

      

      

      
        
          

      

      IN WITNESS WHEREOF, the parties have executed this Agreement, effective as of the Effective Time.

       

      	 	
              LIMINAL SCIENCES, INC.

            
	 	
              PARTICIPANT

            
	 	 
	 	
              By:

            	
              /s/ Alexander Magary

            

      	 	
              Name:

            	
              Alexander Magary

            
	 	
              Title:

            	
              Assistant Secretary

            

      

      

      [Signature Page to Technology and Services Exchange Agreement]

      

      

       

      
        
          

      

      IN WITNESS WHEREOF, the parties have executed this Agreement, effective as of the Effective Time.

       

      	 	
              DETECT, INC.

            
	 	
              PARTICIPANT

            
	 	 
	 	
              By:

            	
              /s/ Alexander Magary

            

      	 	
              Name:

            	
              Alexander Magary

            
	 	
              Title:

            	
              Assistant Secretary

            

       

      

      [Signature Page to Technology and Services Exchange Agreement]

      

      

      
        
          

      

      Joinder for additional Participants

      To Amended and Restated Technology and Services Agreement

       

      The Joining Party below hereby acknowledges, agrees and confirms that, by its execution below, the Joining Party shall, as of the date hereof, be a party to and “Participant” under the Technology and Services
        Exchange Agreement dated February 17, 2021 and effective as of the Effective Time (as defined therein), and agrees to be bound by all of the terms, provisions and conditions contained in such Technology and
        Services Exchange Agreement.

      

      

      	
              Date: August 11, 2021 

              

            
	 
	 	
              JOINING PARTY/ PARTICIPANT

            
	 	 

      	 	
              Joining Party: Protein Evolution, Inc.

            
	 	
              By:

            	
              /s/ Alexander Magary

            	 

      	 	
              Name:

            	
              Alexander Magary

            
	 	
              Title:

            	
              Assistant Secretary

            

      

      

      	 	 	
              QUANTUM-SI INCORPORATED

            
	 	 	 
	
              By:

            	 	
              /s/ Christian LaPointe, Ph.D.

            
	
              Name:

            	 	
              Christian LaPointe, Ph.D.

            
	
              Title:

            	 	
              General Counsel and Corporate Secretary

            

      

      

      
        
          

      

      Joinder for additional Participants

      To Technology and Services Exchange Agreement

       

      The Joining Party below hereby acknowledges, agrees and confirms that, by its execution below, the Joining Party shall, as of the date hereof, be a party to and “Participant” under the Technology and Services
        Exchange Agreement dated as of __________, 2021 and effective as of the Effective Time (as defined therein), and agrees to be bound by all of the terms, provisions and conditions contained in such
        Technology and Services Exchange Agreement.

       

      	 	
              Date: _______ _______

            
	 	 
	 	
              JOINING PARTY/ PARTICIPANT

            
	 	 
	 	
              Joining Party:

            	 

      

      

      	 	
              By:

            	 

      

      

      	 	
              Name:

            	 
	 	 	 
	 	
              Title:

            	 

      

      

      	 	
              QUANTUM-SI INCORPORATED

            
	 	  
	 	
              By:

            	 

      	 	
              Name:

            	 
	 	
              Title:Exhibit 10.2

        

        

      

      Services Work Order No. 1

       

      

      Binders Collaboration

       

      Date:  September 20, 2021

       

      This Services Work Order (“Work Order”) is made pursuant to, and is governed by, the Technology and Services Exchange Agreement (“TSEA”) between Quantum-Si
        Incorporated (“Q-Si”) and Protein Evolution, Inc. (“PEI”), joined by PEI on August 11, 2021 and made effective as of the Effective Time (as defined in the TSEA).  As
        used herein, a “Party” means Q-Si or PEI, and the “Parties” means Q-Si and PEI.  This Work Order is made effective on the last date of signature below, having been
        signed by both Parties.

       

      
        	
                I.

              	
                Overview of Work Order

              

      

       

      The objective of the Work Order is to develop technology and methods in the field of nanobodies and potentially other binders to produce novel biological reagents and data
        relating thereto (as more specifically defined in the Work Plan, the “Reagents”) useful to Q-Si and PEI in their respective core business areas.  PEI will provide research and development services (the “Services”) and (i) deliver all Reagents and (ii) disclose all other biological materials, data, written materials, methods, processes, technologies and other results of the Services (the “Process Results,” and
        collectively with the Reagents, the “Results”) to Q-Si.  The Services will be described in a Work Plan that is approved by both parties.  The parties intend that substantial parts of the Services will be
        subcontracted by PEI to two academic institutions, the University of Wollongong (“UOW”) and the École Supérieure de Physique et de Chimie Industrielles de la Ville de Paris (“ESPCI”). 

        PEI may propose additional subcontractors or collaborators as described in Section III below.

       

      
        	
                II.

              	
                Work Plan and Budget

              

      

       

      The Parties will cooperate to develop a mutually acceptable, reasonably detailed description of the research and development activities, timelines, responsibilities, and
        deliverables (the “Work Plan”).  The Work Plan will include a detailed budget that includes FTEs, materials and any other significant expenditures, all of which shall be charged at cost except as otherwise
        expressly agreed (the “Budget”).  The Services will be performed over a 24 month period, subject to extensions as may be agreed by the Parties.  PEI will provide Q-Si monthly written updates with respect to
        progress under the Work Plan and expenditures against the Budget and quarterly advances described below.  Expenditures against quarterly advances will be accompanied by supporting documentation as reasonably requested by QSI.  The Work Plan will
        specify the content of the updates in more detail.

       

      Q-Si will pay PEI for the Services in accordance with the Budget in an amount not to exceed thirteen million five hundred thousand dollars ($13,500,000), unless otherwise
        agreed by Q-Si in its sole discretion.  PEI will invoice Q-Si quarterly in advance for the Services.  Only specific costs or fees in of PEI’s invoices accompanied by supporting documentation, as reasonably requested by Q-Si, shall be paid.  Q-Si
        will have the right to conduct annual audits of PEI’s expenditures in connection with the Services and the invoices issued by PEI to Q-Si.

       

      
        
          

      

      
      
        	
                III.

              	
                Sponsored Research Agreements

              

      

       

      PEI may enter into sponsored research agreements with ESPCI and UOW, and other third parties that are acceptable to Q-Si (acting reasonably), to perform designated part of the
        Services under the Work Plan, provided that Q-Si has reviewed and approved the sponsored research agreements prior to execution.  ESPCI and UOW each may assign up to 7 researchers to the Work Plan.  PEI will be responsible for providing 20% of the
        sponsored research funding from sources other than Q-SI’s $13,500,000 contribution to the Budget.  Q-Si will be responsible for providing 80% of the sponsored research funding, which will count against Q-Si’s $13,500,000 contribution to the Budget.

       

      
        	
                IV.

              	
                Results and intellectual property rights

              

      

       

      	

            	A.	
              Definitions

            

       

      “Process Results,” “Reagents” and “Results” are defined
        above in Section I.

       

      “Competitive Platform” means any device, software or service that competes with, or that is substantially similar to, any Q-Si Platform.

       

      “PEI Field” means the field of protein and/or molecule design, evolution, discovery, application, and/or characterization, including,
        but not limited to, for therapeutics, diagnostics, agriculture, and/or industrial purposes.

       

      “Process Results Collaboration Patent Rights” shall mean any patents and patent applications claiming the Process Results (or any
        portion thereof) and/or disclosing any data within the Process Results, and any divisional, continuation, continuation-in-part, reissue, reexamination, confirmation, revalidation, registration, patent of addition, renewal, extension or substitute
        thereof, or any patent issuing therefrom or any supplementary protection certificates related thereto, in every jurisdiction throughout the world.

       

      “Q-Si Customer Product” means any diagnostic, prognostic, therapeutic or other product that is initially discovered or developed by a
        Q-Si customer with the use of a Q-Si Platform.

       

      “Q-Si Field” means all fields other than the PEI Field.

       

      “Q-Si Platforms” means Q-Si’s technology platforms, including devices,
          software and services, in existence as of the Effective Date or developed in the future by or on behalf of Q-Si.  The Q-Si Platform as of the Effective Date includes the platform known as Platinum, Carbon and Cloud, which is a protein sequencing
          and analysis platform with the following features:

       

      
        2

        
          

      

      	

            	•	
              time domain sequencing

            

      	

            	•	
              single molecule resolution

            

      	

            	•	
              application agnostic

            

       

      and with known applications in the areas of:

       

      	

            	•	
              Proteomics

            

      	

            	•	
              Single cell

            

      	

            	•	
              Transcriptomics

            

      	

            	•	
              Genomics

            

      	

            	•	
              Metabolomics

            

      	

            	•	
              Drug testing and screening

            

      	

            	•	
              Diagnostics

            

       

      “Reagents Collaboration Patent Rights” shall mean any patents and patent applications claiming the Reagents and/or disclosing any data
        within the Results relating to the Reagents, and any divisional, continuation, continuation-in-part, reissue, reexamination, confirmation, revalidation, registration, patent of addition, renewal, extension
        or substitute thereof, or any patent issuing therefrom or any supplementary protection certificates related thereto, in every jurisdiction throughout the world.

       

      	

            	B.	
              Ownership of Results

            

       

      The parties agree that, notwithstanding Section 3.2 of the TSEA, Q-Si will own all rights, including intellectual property rights, in and to the Reagents, and PEI will own all
        rights, including intellectual property rights, in and to the Process Results.

       

      	

            	C.	
              Patent Prosecution, Maintenance and Enforcement

            

       

      
        	 	
                1.

              	
                The Reagents Collaboration Patent Rights

              

      

       

      Q-Si will have sole control over patent prosecution and sole rights to enforce any patents directed to the Reagents, at its own expense.  To the extent reasonably possible in
        light of filing deadlines, Q-Si will provide PEI with advance copies of any draft patent applications directed to the Reagents and responses to office actions or similar communications, and Q-Si will reasonably consider PEI’s comments.  Q-Si shall
        have the right to retain all proceeds of any enforcement of the Reagents, including any damages awards and settlements.  PEI will cooperate with Q-Si, including executing documents and joining any enforcement or patent defense proceedings where
        required for standing or otherwise deemed advisable by Q-Si, and Q-Si will reimburse PEI for its reasonable, documented out-of-pocket expenses incurred as a result of such cooperation.

       

      
        3

        
          

      

      
        
          
            	 	
                    2.

                  	
                    The Process Results Collaboration Patent Rights

                  

          

        

      

       

      PEI will have sole control over patent prosecution and sole rights to enforce any patents directed to the Process Results, at its own expense.  To the extent reasonably
        possible in light of filing deadlines, PEI will provide Q-Si with advance copies of any draft patent applications directed to the Process Results and responses to office actions or similar communications, and PEI will reasonably consider Q-Si’s
        comments.  PEI shall have the right to retain all proceeds of any enforcement of the Process Results, including any damages awards and settlements.  Q-Si will cooperate with PEI, including executing documents and joining any enforcement or patent
        defense proceedings where required for standing or otherwise deemed advisable by PEI, and PEI will reimburse Q-Si for its reasonable, documented out-of-pocket expenses incurred as a result of such cooperation.

       

      The Parties agree that the license granted to the Originating Party in Section 3.2 of the TSEA does not apply to the Reagents or Process Results under this Work Order.

       

      	

            	D.	
              Licenses

            

       

      PEI hereby grants Q-Si a royalty-free, fully-paid up, perpetual, worldwide, non-exclusive, sublicensable license under the PEI’s rights in the Process Results, including under
        any Process Result Collaboration Patents, to make, have made, use, have used, import, have imported, export, have exported, sell, offer for sale and have sold products and services, and to copy, create derivative works from and otherwise exploit
        the Process Results in the Q-Si Field.  In consideration of Q-Si’s contribution to the Budget, PEI covenants that it and its successors will not grant a license under PEI’s rights in the Process Results, including under any Process Result
        Collaboration Patents, to any entity that is developing or commercializing a Competitive Platform.

       

      PEI hereby grants Q-Si a royalty-free, fully-paid up, perpetual, worldwide, non-exclusive, sublicensable license under PEI’s rights in the Process Results, including under any
        Process Result Collaboration Patents, to make, have made, use, have used, import, have imported, export, have exported, sell, offer for sale and have sold the Q-Si Platforms and Q-Si Customer Products.

       

      Q-Si hereby grants PEI a royalty-free, fully-paid up, perpetual, worldwide, co-exclusive, sublicensable license under the rights in the Reagents, including under any Reagents
        Collaboration Patents, to make, have made, use, have used, import, have imported, export, have exported, sell, offer for sale and have sold products and services, and to copy, create derivative works from and otherwise exploit the Process Results
        in the PEI Field.  “Co-exclusive” means that Q-Si retains the rights to use the Reagents in the PEI Field in connection with the Q-Si Platforms, but other than licenses with respect to Q-Si Customer Products, Q-Si will not grant any other licenses
        to third parties.

       

      	

            	E.	
              No implied licenses

            

       

      Nothing in this Work Order affects the parties’ respective rights with respect to Q-Si’s Platinum platform or any improvements thereto, which are the subject of a separate
        agreement between the parties.  The only rights granted by one Party to the other Party under this Work Order are the rights expressly set forth herein.  There are no implied licenses.

       

      
        4

        
          

      

      
        	
                V.

              	
                Termination and Winding Down

              

      

       

      This Work Order will continue until Reagents are produced to Q-Si’s satisfaction, or one Party terminates the Work Order by giving 180 days’ written termination notice.  Upon
        notice of termination, PEI will initiate an orderly wind-down of activities, including under any sponsored research agreements.  Unless otherwise agreed by Q-SI, the sponsored research agreements will not include any pre-payments for periods
        exceeding 180 days, and will permit termination for convenience by PEI upon (at most) 180 days’ notice.

       

      
        5

        
          

      

      Accepted and agreed by the Parties by their duly authorized representatives:

       

      	
              QUANTUM-SI INCORPORATED

            	 	
              PROTEIN EVOLUTION, INC.

            
	   
	
              By:

            	
              /s/ Christian LaPointe

            	 	
              By:

            	
              /s/ Alexander C. Magary

            

      

      

      	
              Name:

            	
              Christian LaPointe

            	 	
              Name:

            	
              Alexander C. Magary

            

      

      

      	
              Title:

            	
              General Counsel

            	 	
              Title:

            	
              VP, Legal & Asst. Corp. Secretary

            

      

      

      	
              Date:

            	
              9/20/2021

            	 	
              Date:

            	
              9/20/2021

            

      

      

       

      

       6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00336-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00336-of-00352.parquet"}]]